Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917474 | 0.86 | MET (0.54) | METSMN1; SMN2LMNAALDH1A1NR3C1 | |
| SCHEMBL17035965 | 0.80 | LMNA (0.41) | METSMN1; SMN2LMNAALDH1A1NR3C1 | |
| SCHEMBL31023643 | 0.79 | NPC1 (0.57) | METSMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL17953926 | 0.78 | PDE4D (0.48) | METSMN1; SMN2LMNAALDH1A1NR3C1 | |
| SCHEMBL17035969 | 0.78 | LMNA (0.39) | METSMN1; SMN2LMNAALDH1A1NR3C1 | |
| SCHEMBL17035966 | 0.77 | HRH1 (0.49) | METSMN1; SMN2LMNAALDH1A1NR3C1 | |
| SCHEMBL9192602 | 0.77 | SMN1; SMN2 (0.47) | METSMN1; SMN2LMNAALDH1A1KDM5A | |
| SCHEMBL29660594 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNAALDH1A1CHEK2HPGD | |
| SCHEMBL17035964 | 0.73 | ALDH1A1 (0.46) | METSMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL7097024 | 0.73 | ALDH1A1 (0.51) | METSMN1; SMN2LMNAALDH1A1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | MET 3487/4885SMN1; SMN2 2305/4885LMNA 671/4885 |
| US-20160213677-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | MET 3487/4885SMN1; SMN2 2305/4885LMNA 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.